+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Biokinetics and dosimetry in patients administered with111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with90Y-DOTATOC



Biokinetics and dosimetry in patients administered with111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with90Y-DOTATOC



European Journal of Nuclear Medicine and Molecular Imaging 26(8): 877-886




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 062772766

Download citation: RISBibTeXText

DOI: 10.1007/s002590050462


Related references

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. European Journal of Nuclear Medicine 26(8): 877-886, 1999

Receptor-mediated radiotherapy with90Y-DOTA-D-Phe1-Tyr3-octreotide. European Journal of Nuclear Medicine and Molecular Imaging 28(4): 426-434, 2001

Organ and tumor dosimetry of 177Lu-DOTA-Tyr3-octreotate and 90Y-DOTA-Tyr3-octreotide A preliminary study in 2 patients. Journal of Nuclear Medicine 43(5 Suppl.): 316P, 2002

Bone marrow dose results in peptide receptor radionuclide therapy with 90Y-DOTA-Tyr3-Octreotide, 111In-DTPA-Octreotide and 177Lu-DOTA-Octreotate Importance of dosimetry model. Journal of Nuclear Medicine 43(5 Suppl.): 90P, 2002

Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 33(5): 532-540, 2006

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 31(7): 1038-1046, 2004

Rapid and high-yield solution-phase synthesis of DOTA-Tyr3-octreotide and DOTA-Tyr3-octreotate using unprotected DOTA. Tetrahedron Letters 44(11): 2393-2396, 10 March, 2003

Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits. Applied Radiation and Isotopes 64(7): 792-797, 2006

68Ga-DOTA-D Phe1-Tyr3-Octreotide (DOTATOC)-PET/CT in a Suspected Case of Recurrent Meningioma. Indian Journal of Nuclear Medicine 32(2): 164, 2017

Biodistribution and dosimetry of indium-111 labeled DOTA-Tyr3-octreotide in patients with neuroendocrine tumors. Journal of Nuclear Medicine 39(5 Suppl. ): 221P, 1998

131I]-TYR3-octreotide: clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumors. Nuclear Medicine and Biology 27(8): 809-813, 2000

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 31(10): 1386-1392, 2004

Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue. Clinical Oncology ) 12(2): 121-123, 2000

Detection of somatostatin receptor-positive tumours using the new99mTc-tricine-HYNIC-d-Phel-Tyr3-octreotide: first results in patients and comparison with111In-DTPA-D-Phe1-octreotide. European Journal of Nuclear Medicine and Molecular Imaging 27(10): 1580-1580, 2000

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Annals of Oncology 12(7): 941-945, 2001